CN118829642A - 二酰基甘油激酶(DGK)α抑制剂及其用途 - Google Patents

二酰基甘油激酶(DGK)α抑制剂及其用途 Download PDF

Info

Publication number
CN118829642A
CN118829642A CN202380024556.1A CN202380024556A CN118829642A CN 118829642 A CN118829642 A CN 118829642A CN 202380024556 A CN202380024556 A CN 202380024556A CN 118829642 A CN118829642 A CN 118829642A
Authority
CN
China
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380024556.1A
Other languages
English (en)
Chinese (zh)
Inventor
陆洪福
余华星
丁晓
任峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingsi Intelligent Technology Intellectual Property Co ltd
Original Assignee
Yingsi Intelligent Technology Intellectual Property Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingsi Intelligent Technology Intellectual Property Co ltd filed Critical Yingsi Intelligent Technology Intellectual Property Co ltd
Publication of CN118829642A publication Critical patent/CN118829642A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380024556.1A 2022-03-01 2023-03-01 二酰基甘油激酶(DGK)α抑制剂及其用途 Pending CN118829642A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2022078655 2022-03-01
CNPCT/CN2022/078655 2022-03-01
CNPCT/CN2022/091215 2022-05-06
CN2022091215 2022-05-06
CN2022128282 2022-10-28
CNPCT/CN2022/128282 2022-10-28
CN2023071962 2023-01-12
CNPCT/CN2023/071962 2023-01-12
PCT/CN2023/078973 WO2023165509A1 (en) 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
CN118829642A true CN118829642A (zh) 2024-10-22

Family

ID=87883015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380024556.1A Pending CN118829642A (zh) 2022-03-01 2023-03-01 二酰基甘油激酶(DGK)α抑制剂及其用途

Country Status (7)

Country Link
US (1) US20250214990A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507915A (cg-RX-API-DMAC7.html)
CN (1) CN118829642A (cg-RX-API-DMAC7.html)
AR (1) AR128668A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342478A (cg-RX-API-DMAC7.html)
WO (1) WO2023165509A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075747A1 (en) * 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
WO2021105115A1 (en) * 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294148A (en) * 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN115362003B (zh) * 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.

Also Published As

Publication number Publication date
EP4486745A4 (en) 2026-03-11
EP4486745A1 (en) 2025-01-08
US20250214990A1 (en) 2025-07-03
AR128668A1 (es) 2024-06-05
TW202342478A (zh) 2023-11-01
JP2025507915A (ja) 2025-03-21
WO2023165509A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
CN118871438A (zh) 二酰基甘油激酶(DGK)α抑制剂及其用途
CN114075195B (zh) 嘧啶酮衍生物及其在药物中的应用
EP2702064A1 (en) Kinase inhibitors
CN118434722A (zh) 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途
CN119630670A (zh) TNFα活性调节剂及其用途
TW202342478A (zh) 二醯基甘油激酶(DGK)α抑制劑及其用途
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
KR102755652B1 (ko) 고리형 디뉴클레오티드 유사체, 이의 약학 조성물 및 용도
JP2025503012A (ja) Parp1阻害薬及びその使用
CN118974048A (zh) 膜相关的酪氨酸和苏氨酸特异性cdc2抑制激酶(pkmyt1)抑制剂及其用途
CN119630662A (zh) Cbl-b抑制剂及其应用方法
CN118871439A (zh) 外核苷酸焦磷酸酶-磷酸二酯酶(enpp1)抑制剂及其用途
CN113773335A (zh) 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途
WO2020163118A1 (en) Phosphorus imidazoquinoline amine derivatives, pharmaceutical compositions and therapeutic methods thereof
CN121941684A (zh) Cbl-b抑制剂及其使用方法
CN121175313A (zh) Nlrp3炎症小体抑制剂及其用途
AU2023224815A1 (en) Compound as fak inhibitor and use thereof
TW202237101A (zh) Ctla-4小分子降解劑及其應用
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
HK40117800A (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
HK40116343A (en) Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof
WO2025261355A1 (en) Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2023193759A1 (en) Hpk1 antagonists and uses thereof
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途
WO2025252075A1 (en) Novel compounds as salt-inducible kinases inhibitors and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination